約70%的上皮性卵巢癌患者確診時已屬晚期。當無法進行初次最佳手術時，新輔助化療後進行中間減瘤手術是其中一種治療選擇。然而，對於手術的最佳時機並無共識。CA125是卵巢癌中眾所周知的腫瘤標記。

適應症：Ovarian Cancer、Fallopian Tube Cancer、Primary Peritoneal Carcinoma

收案條件

Patients aged 18 years old or older
Patients with Eastern Cooperative Oncology Group score 0-1 within 28 days prior to recruitment
Patients who can sign the informed consent
Patients with stage III-IV histologically or cytologically confirmed epithelial ovarian cancer (EOC), fallopian tube or primary peritoneal cancer not amenable for PDS
Patients who have baseline computed tomography (CT) of thorax, abdomen and pelvis.
Patients who are planned for neoadjuvant chemotherapy (NACT) using 3-weekly carboplatin and paclitaxel. Those who have received one cycle of NACT may be eligible if the CA125 schedule of the study group can be matched.
Patients who have an evaluable CA125 level at baseline (i.e., baseline level is at least 2x upper limit of normal)
Patients who agree for chemotherapy and interval debulking surgery (IDS) if the disease becomes operable after NACT
Patients with adequate hematologic, liver and renal functions for chemotherapy
Patients who agree to receive adjuvant chemotherapy after IDS. The total number of NACT and adjuvant chemotherapy should be four or above, up to maximum of 9 cycles.
Patients who have childbearing potential should practice highly effective contraception throughout the study until at least 30 days after completion of the treatment.
Patients must have either germline and / or somatic BRCA test, or homologous recombination deficiency (HRD) test.

Patients who have borderline malignancy, or non-EOC like germ cell or sex cord tumor, or metastatic diseases from other origins
Patients with mucinous and neuroendocrine histology
Patients with history of other malignancies within five years
Patients who are eligible for primary debulking surgery (PDS)
Patients who cannot undergo PDS because of parametrial and/or vaginal involvement alone
Patients who are not fit for PDS because of medical morbidities or refusal of operation
Patients who have already started NACT outside the study centers, except those who have received only one cycle within 7 days and the baseline CA125 value within 3 days of NACT (normal cut-off 35 U/ml) is available
Patients who participate in other interventional studies
Patients who are pregnant or breastfeeding
Patients who have contraindications to platinum-based chemotherapy
Patents with active tuberculosis, history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) are excluded.

收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。

晚期卵巢癌中間減瘤手術的個人化時機